Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from GlucoTrack ( (GCTK) ) is now available.
On June 12, 2025, Glucotrack, Inc. announced a 1-for-60 reverse stock split of its common stock, effective June 16, 2025. This move aims to comply with NASDAQ’s $1.00 minimum bid price requirement and attract broader institutional investment. The reverse stock split will reduce the total outstanding shares from approximately 32.5 million to about 542,356, while maintaining the ownership percentage of each stockholder. The action was approved by stockholders on May 22, 2025, and is intended to ensure the company’s continued listing on the Nasdaq Capital Market.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.
GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.
To see Spark’s full report on GCTK stock, click here.
More about GlucoTrack
Glucotrack, Inc. is a medical technology company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently working on a long-term implantable continuous blood glucose monitoring system.
Average Trading Volume: 6,308,550
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.5M
Learn more about GCTK stock on TipRanks’ Stock Analysis page.